시장보고서

상품코드

2078250

척수 손상 치료제 시장 : 약제 종류별, 적응증별, 용도별, 투여 경로별, 유통 채널별, 지역별

Spinal Cord Injury Therapeutics Market, By Drug Type, By Indication, By Application, By Route of Administration, By Distribution Channel, By Geography

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,704,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,428,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,898,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

척수 손상 치료제 시장은 2026년에 86억 8,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 127억 1,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 5.6%로 성장할 것으로 전망됩니다.

분석 범위		분석 상세
기준 연도	2025년	시장 규모(2026년)	86억 8,000만 달러
실적 데이터	2020-2024년	예측 기간	2026-2033년
예측 기간 CAGR(2026-2033년)	5.60%	예측 금액(2033년)	127억 1,000만 달러

세계 척수 손상 치료제 시장은 코르티코스테로이드, 비스테로이드성 항염증제(NSAID), 근이완제, 항우울제 등 척수 손상 치료에 사용되는 약물로 구성되어 있습니다. 척수 손상에는 완전 척수 손상과 불완전 척수 손상 두 가지 유형이 있으며, 그 원인으로는 뇌 손상, 외상, 척수로의 혈액 공급 중단, 종양이나 감염에 의한 척수 압박 등이 있습니다.

시장 역학

주요 기업들은 세계 척수 손상 치료제 시장에서 입지를 강화하기 위해 제품 승인 획득에 주력하고 있습니다. 예를 들어, 2020년 9월, 애브비(AbbVie Inc.)는 척수 손상 치료를 목적으로 임상시험 중인 단일클론 항체 RGMa 억제제 ‘엘레자누맙(Elezanumab)’에 대해 미국 식품의약국(FDA)으로부터 희귀질환 치료제 지정 및 패스트트랙 지정을 받았습니다.

본 보고서의 주요 특징

본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한, 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 인사이트도 제공하고 있습니다.
전 세계 척수 손상 치료제 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 수록하고 있습니다.
본 보고서의 인사이트를 바탕으로, 마케팅 담당자 및 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대, 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
'세계 척수 손상 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
이해관계자들은 전 세계 척수 손상 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 8.68 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.60%	2033 Value Projection:	USD 12.71 Bn

The global spinal cord injury therapeutics market comprises therapeutics used for the treatment of spinal cord injury such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAID'S), muscle relaxants, and anti-depressants. There are two types of spinal cord injuries including complete spinal cord injury and incomplete spinal cord injury and various causes of spinal cord injuries include brain injury, trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections.

Market Dynamics

Key players are focusing on product approvals to strengthen their position in the global spinal cord injury therapeutics market. For instance, in September 2020, AbbVie Inc., received an orphan drug and fast track designation from the U.S. Food and Drug Administration for Elezanumab, an investigational monoclonal antibody RGMa inhibitor for the treatment of spinal cord injury.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global spinal cord injury therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc., RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc., MSN Laboratories Private Limited, and Lannett Co Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global spinal cord injury therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal cord injury therapeutics market

Detailed Segmentation:

Global Spinal Cord Injury Therapeutics Market, By Injury Type (Revenue, USD Bn, 2021 - 2033)
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
Global Spinal Cord Injury Therapeutics Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
Global Spinal Cord Injury Therapeutics Market, By Application (Revenue, USD Bn, 2021 - 2033)
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
Global Spinal Cord Injury Therapeutics Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Oral
Intravenous
Global Spinal Cord Injury Therapeutics Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Spinal Cord Injury Therapeutics Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Injury Type
  - Complete Spinal Cord Injury
  - Incomplete Spinal Cord Injury
- By Drug Type
  - Corticosteroids
  - Muscle Relaxants and Anti-spastic drugs
  - Non-steroidal Anti-inflammatory drugs (NSAIDs)
  - Anti-depressants
  - Anticonvulsants
  - Others
- By Application
  - Autonomic Dysreflexia (AD)
  - Spasticity & Inflammation
  - Pain Management
  - Depression
- By Route of Administration
  - Oral
  - Intravenous
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - U.S.
  - Canada
Latin America
- By Injury Type
  - Complete Spinal Cord Injury
  - Incomplete Spinal Cord Injury
- By Drug Type
  - Corticosteroids
  - Muscle Relaxants and Anti-spastic drugs
  - Non-steroidal Anti-inflammatory drugs (NSAIDs)
  - Anti-depressants
  - Anticonvulsants
  - Others
- By Application
  - Autonomic Dysreflexia (AD)
  - Spasticity & Inflammation
  - Pain Management
  - Depression
- By Route of Administration
  - Oral
  - Intravenous
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Injury Type
  - Complete Spinal Cord Injury
  - Incomplete Spinal Cord Injury
- By Drug Type
  - Corticosteroids
  - Muscle Relaxants and Anti-spastic drugs
  - Non-steroidal Anti-inflammatory drugs (NSAIDs)
  - Anti-depressants
  - Anticonvulsants
  - Others
- By Application
  - Autonomic Dysreflexia (AD)
  - Spasticity & Inflammation
  - Pain Management
  - Depression
- By Route of Administration
  - Oral
  - Intravenous
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Injury Type
  - Complete Spinal Cord Injury
  - Incomplete Spinal Cord Injury
- By Drug Type
  - Corticosteroids
  - Muscle Relaxants and Anti-spastic drugs
  - Non-steroidal Anti-inflammatory drugs (NSAIDs)
  - Anti-depressants
  - Anticonvulsants
  - Others
- By Application
  - Autonomic Dysreflexia (AD)
  - Spasticity & Inflammation
  - Pain Management
  - Depression
- By Route of Administration
  - Oral
  - Intravenous
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Injury Type
  - Complete Spinal Cord Injury
  - Incomplete Spinal Cord Injury
- By Drug Type
  - Corticosteroids
  - Muscle Relaxants and Anti-spastic drugs
  - Non-steroidal Anti-inflammatory drugs (NSAIDs)
  - Anti-depressants
  - Anticonvulsants
  - Others
- By Application
  - Autonomic Dysreflexia (AD)
  - Spasticity & Inflammation
  - Pain Management
  - Depression
- By Route of Administration
  - Oral
  - Intravenous
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Injury Type
  - Complete Spinal Cord Injury
  - Incomplete Spinal Cord Injury
- By Drug Type
  - Corticosteroids
  - Muscle Relaxants and Anti-spastic drugs
  - Non-steroidal Anti-inflammatory drugs (NSAIDs)
  - Anti-depressants
  - Anticonvulsants
  - Others
- By Application
  - Autonomic Dysreflexia (AD)
  - Spasticity & Inflammation
  - Pain Management
  - Depression
- By Route of Administration
  - Oral
  - Intravenous
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
AbbVie Inc.
Pfizer Inc.
Reddy's Laboratories Ltd.
Zydus Cadila
ReNetX Bio, Inc.
InVivo Therapeutics Holdings
Lineage Cell Therapeutics, Inc.
Kringle Pharma, Inc.
Acorda Therapeutics, Inc.
Bioaxone Biosciences, Inc.
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc.
ScieGen Pharmaceuticals, Inc.
MSN Laboratories Private Limited
Lannett Co Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Application
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Spinal Cord Injury Therapeutics Market, By Drug Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Muscle Relaxants and Anti-spastic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Non-steroidal Anti-inflammatory Drugs (NSAID'S)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Anti-depressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

5. Global Spinal Cord Injury Therapeutics Market, By Indication, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Complete Spinal Cord Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Incomplete Spinal Cord Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

6. Global Spinal Cord Injury Therapeutics Market, By Application, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Autonomic Dysreflexia (AD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Spasticity and Inflammation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

7. Global Spinal Cord Injury Therapeutics Market, By Route of Administration, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

8. Global Spinal Cord Injury Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

9. Global Spinal Cord Injury Therapeutics Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 - 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Reddy's Laboratories Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Zydus Cadila
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ReNetX Bio, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- InVivo Therapeutics Holdings
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Lineage Cell Therapeutics, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Kringle Pharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Acorda Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bioaxone Biosciences, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- RespireRx Pharmaceuticals Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- NervGen
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Rising Pharmaceuticals, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ScieGen Pharmaceuticals, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- MSN Laboratories Private Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Lannett Co Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Other Prominent Players
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

11. Section

References
Research Methodology
About us and Sales Contact

척수 손상 치료제 시장 : 약제 종류별, 적응증별, 용도별, 투여 경로별, 유통 채널별, 지역별